Braun, Theodore P. http://orcid.org/0000-0002-6248-2143
Estabrook, Joseph
Schonrock, Zachary
Curtiss, Brittany M. http://orcid.org/0000-0002-5274-8323
Darmusey, Lucie http://orcid.org/0000-0002-0583-8422
Macaraeg, Jommel
Enright, Trevor
Coblentz, Cody
Callahan, Rowan
Yashar, William http://orcid.org/0000-0002-8850-9850
Taherinasab, Akram
Mohammed, Hisham
Coleman, Daniel J.
Druker, Brian J. http://orcid.org/0000-0001-8331-8206
Demir, Emek
Lusardi, Theresa A. http://orcid.org/0000-0003-0699-5662
Maxson, Julia E. http://orcid.org/0000-0002-3871-7221
Funding for this research was provided by:
OHSU Center for Early Detection Advanced Research
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (R01HL157147)
Article History
Received: 4 December 2021
Revised: 29 November 2022
Accepted: 6 December 2022
First Online: 16 December 2022
Competing interests
: BJD potential competing interests-- SAB: Aileron Therapeutics, Therapy Architects (ALLCRON), Cepheid, Vivid Biosciences, Celgene, RUNX1 Research Program, Novartis, Gilead Sciences (inactive), Monojul (inactive); SAB & Stock: Aptose Biosciences, Blueprint Medicines, EnLiven Therapeutics, Iterion Therapeutics, Third Coast Therapeutics, GRAIL (SAB inactive); Scientific Founder: MolecularMD (inactive, acquired by ICON); Board of Directors & Stock: Amgen; Board of Directors: Burroughs Wellcome Fund, CureOne; Joint Steering Committee: Beat AML LLS; Founder: VB Therapeutics; Research Funding: EnLiven Therapeutics; Clinical Trial Funding: Novartis, Bristol-Myers Squibb, Pfizer; Royalties from Patent 6958335 (Novartis exclusive license) and OHSU and Dana-Farber Cancer Institute (one Merck exclusive license and one CytoImage, Inc. exclusive license). The remaining authors declare no competing interests.